Neurocrine Biosciences (NBIX) FCF Margin (2010 - 2026)

Neurocrine Biosciences has reported FCF Margin for 16 years, with the latest figure at 16.78% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 734.0% year-over-year to 16.78%; the trailing twelve-month figure through Mar 2026 stood at 26.8% (up 681.0% YoY), and the FY2025 full-year result was 26.17%, up 252.0% from the prior year.
• FCF Margin for Q1 2026 stood at 16.78%, down from 44.07% in the prior quarter.
• The five-year high for FCF Margin was 646.5% in Q2 2022, with the low at 29.92% in Q1 2023.
• Historically, FCF Margin has averaged 57.1% across 5 years, with a median of 25.07% in 2024.
• Annual changes were most pronounced in 2022 — FCF Margin jumped 60998 bps — and 2023, when it slumped 61007 bps.
• Neurocrine Biosciences' FCF Margin stood at 30.87% in 2022, then sank by 40 bps to 18.65% in 2023, then soared by 101 bps to 37.47% in 2024, then increased by 18 bps to 44.07% in 2025, then tumbled by 62 bps to 16.78% in 2026.
• The last three FCF Margin figures came in at 16.78% (Q1 2026), 44.07% (Q4 2025), and 31.46% (Q3 2025), per Business Quant data.